- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Swiss Pharmaceuticals & Biotech Strong Balance Sheet Stocks
U.S. Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
14 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SFZNSiegfried Holding | CHF773.00 | -3.9% | 22.8% | CHF3.2b | CHF981.88 | PE46.5x | E16.0% | 0.4% | ||
| VIFNVifor Pharma | CHF161.90 | -1.3% | 18.3% | CHF10.5b | CHF152.00 | PE49.2x | E12.4% | 1.2% | ||
| KURNKuros Biosciences | CHF1.97 | -0.5% | -6.6% | CHF64.6m | n/a | PS5.5x | n/a | n/a | ||
| ROGRoche Holding | CHF367.35 | -1.0% | 16.6% | CHF297.4b | CHF403.88 | PE21x | E8.6% | 2.5% | ||
| TECNTecan Group | CHF453.60 | -3.6% | 2.6% | CHF5.8b | CHF613.75 | PE38.3x | E10.5% | 0.5% | ||
| ADXNAddex Therapeutics | CHF0.95 | -7.8% | -41.0% | CHF36.0m | n/a | PS7.8x | E42.1% | n/a | ||
| SKANSKAN Group | CHF75.20 | 0.4% | 385.2% | CHF1.7b | CHF91.00 | PE151.4x | E26.3% | 2.8% | ||
| PPGNPolyPeptide Group | CHF98.90 | -5.1% | n/a | CHF3.3b | CHF142.24 | PE65.1x | E12.3% | n/a | ||
| BANBBachem Holding | CHF558.00 | -0.2% | 47.6% | CHF8.2b | CHF851.25 | PE83.7x | E23.5% | 0.6% | ||
| MOLNMolecular Partners | CHF23.40 | 5.2% | 12.8% | CHF755.6m | CHF27.58 | PS79.6x | E-16.6% | n/a | ||
| LONNLonza Group | CHF663.80 | -2.0% | 13.9% | CHF49.3b | CHF798.44 | PE89.7x | E18.7% | 0.5% | ||
| WBIOWockhardt Bio | CHF1.01 | 0% | -64.8% | CHF52.5m | n/a | PE1.5x | n/a | 0% | ||
| NWRNNewron Pharmaceuticals | CHF1.55 | -1.4% | -42.2% | CHF27.6m | CHF4.77 | PS4.9x | E10.0% | n/a | ||
| IDIAIdorsia | CHF20.32 | 14.4% | -28.2% | CHF3.6b | CHF27.47 | PS99.4x | E32.0% | n/a |
Page 1 of 1